A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov
This article was originally published in PharmAsia News
Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov spoke about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.
You may also be interested in...
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.